Clinical Trials

Offices

For This Service

To learn more, please call our Research Department at (513) 936-5388 or (888) 649-4800. Or email abradley@ohcmail.com

  • Non-Small Cell

    NEOADJUVANT SELECT STAGE IB, II AND III
    Study number:
    LUN 186 SCRI
    Protocol title:
    Phase II Trial of Preoperative Pemetrexed and Carboplatin in Patients with Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
    Status:
    Open 
  • ADJUVANT/POST-OP
    Study number:
    LUN 142 SCRI
    Protocol title:
    A Randomized Phase II Trial of Adjuvant Carboplatin, Docetaxel, Avastin, and Erlotinib versus Chemotherapy alone in Patients with Resected Non-Small Cell Lung Cancer
    Status:
    Open
  • FIRST LINE, ADVANCED    
Study number: 
           Pharmatech NSC PSHC108-009
Protocol title:
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-line Treatment, Followed by Bevacizumab plus Pemetrexed versus Pemetrexed Alone as Second-line Treatment of Stage IIIB or IV Non-small Cell Lung Cancer (NSCLC)
Status:
Open

Study Number: LUN 201  SCRI
Protocol title:

Randomized Phase 3 Trial of Gemcitabine/Carboplatin with or without BSI-201 (a PARP1 Inhibitor) in Patients with Previously Untreated Advanced Squamous Cell Lung Cancer

Status: Open

 


 
  • FIRST LINE, POOR PERFORMANCE, ADVANCED
    Study number:
    LUN 196 SCRI Service
    Protocol title:
    TOPPS (Trial of Poor Performance Status Patients): Randomized Phase II Trial of Pemetrexed vs. Pemetrexed/Bevacizumab vs. Pemetrexed/Carboplatin/Bevacizumab in Patients with Stage III/IV Non-Small-Cell Lung Cancer and ECOG Performance Status 2
    Status:
    Open 
  • RELAPSED/REFRACTORY STAGE III
    Study number:
    LUN 187 H3E-MC-JMIG Eli Lily & Company
    Protocol title:
    Phase III Study of Pemetrexed, Cisplatin and Radiotherapy Followed by Consolidation Pemetrexed versus Etoposide, Cisplatin and Radiotherapy Followed by Consolidation Cytotoxic chemotherapy of Choice in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer Other than Predominantly Squamous Cell Histology
    Status:
    Open
     


  • Small Cell

    EXTENSIVE STAGE FIRST LINE
    Study number:
    LUN 199 SCRI
    Protocol title:
    A Phase II Trial of Amburubicin and Carboplatin with Pegfilgrastim in Patients with Extensive-Stage Small Cell Lung Cancer
    Status:
    Open - currently on hold to enrollment
  • EXTENSIVE STAGE SECOND LINE/RELAPSED
    Study number:
    LUN 198 A6012212US Nippon Kayaku Co., Ltd.
    Protocol title:
    A Phase II Study of NK012 in Sensitive and Refractory Relapsed Small-Cell Lung cancer (SCLC)
    Status:
    Open- Relapsed, Refractory cohort only